AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MESOBLAST LTD

1.715

-0.005-0.29%

Volume:3.01M

Turnover:5.09M

Market Cap:2.19B

PE:-12.00

High:1.725

Open:1.700

Low:1.655

Close:1.720

Loading ...

Overview Company News Filings

Why Bellevue Gold, Mesoblast, Pilbara Minerals, and Wesfarmers shares are dropping today

Why the Mesoblast share price is diving 18% after an FDA win

MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease

Mesoblast Is Maintained at Overweight by Piper Sandler

U.S.-Listed Shares of Mesoblast up 44% After FDA Approves Cell Therapy for Graft-Versus-Host Disease

THOMSON REUTERS

BUZZ-Mesoblast gains on FDA nod for graft-versus-host disease cell therapy

U.S.-Listed Shares of Mesoblast Surge 49% Premarket After FDA Approves Cell Therapy for Graft-Versus-Host Disease

THOMSON REUTERS

Why Champion Iron, EBR Systems, Mesoblast, and Patriot Battery Metals shares are surging today

BUZZ-Australia's Mesoblast at 4-yr high on US FDA nod for cell therapy

Mesoblast’s Ryoncil becomes first cell therapy approved in the US for acute graft-versus-host disease

Mesoblast Receives US FDA Approval for Mesenchymal Stromal Cell Therapy; Shares Hit Four-Year High

MT Newswires Live

Mesoblast’s Ryoncil® Is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy

THOMSON REUTERS

Mesoblast share price rockets 30% on big US FDA news

Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index

BRIEF-FDA Approves First Mesenchymal Stromal Cell Therapy To Treat Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Ltd-FDA Approves Mesoblast Ryoncil

THOMSON REUTERS

US FDA approves Mesoblast's cell therapy for graft-versus-host disease

FDA: Approved Ryoncil Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease in Pediatric Patients 2 Months of Age & Older

THOMSON REUTERS

FDA: Granted Approval of Ryoncil to Mesoblast, Inc.

THOMSON REUTERS

BRIEF-Mesoblast To Be Added To Nasdaq Biotechnology Index

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news?page=7"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.715,"timestamp":1746676750485,"preClose":1.72,"halted":0,"volume":3012250,"delay":0,"nameEN":"MESOBLAST LTD","floatShares":784305641,"shares":1277239284,"eps":-0.14286289417247972,"marketStatus":"Trading","change":-0.005,"latestTime":"05-08 13:59:14 AEST","open":1.7,"high":1.725,"low":1.655,"amount":5089438,"amplitude":0.040698,"askPrice":1.715,"askSize":19269,"bidPrice":1.71,"bidSize":22819,"shortable":3,"etf":0,"ttmEps":-0.14286289417247972,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746684000000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":1.72,"openAndCloseTimeList":[[1746662400000,1746684000000]],"volumeRatio":0.960115,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":784305641,"roa":"-4.85%","roe":"-21.31%","lyrEps":-0.138029,"volumeRatio":0.960115,"shares":1277239284,"dividePrice":0,"high":1.725,"amplitude":0.040698,"preClose":1.72,"low":1.655,"week52Low":0.88,"pbRate":"3.07","psRate":"249.49","week52High":3.37,"institutionHeld":0,"latestPrice":1.715,"committee":0.084347,"eps":-0.14286289417247972,"divideRate":0,"volume":3012250,"delay":0,"ttmEps":-0.14286289417247972,"open":1.7,"prevYearClose":3.1,"prevWeekClose":1.845,"prevMonthClose":1.795,"prevQuarterClose":1.96,"fiveDayClose":1.88,"twentyDayClose":1.615,"sixtyDayClose":3.02},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:7,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492533154","title":"Why Bellevue Gold, Mesoblast, Pilbara Minerals, and Wesfarmers shares are dropping today","url":"https://stock-news.laohu8.com/highlight/detail?id=2492533154","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492533154?lang=en_us&edition=fundamental","pubTime":"2024-12-20 09:23","pubTimestamp":1734657817,"startTime":"0","endTime":"0","summary":"In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week in a disappointing fashion. At the time of writing, the benchmark index is down a further 1% to 8,086.9 points. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/20/why-bellevue-gold-mesoblast-pilbara-minerals-and-wesfarmers-shares-are-dropping-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BGL.AU","BK7095","BK7511","MSB.AU","BK7041","MTX","BK4139","BK7153","BK7104","MESO","BK4109","MSC","BK7504","BK7501","BK4575","XJO.AU","BK4150","BK7067","BK7507","PLS.AU","BK7508","WES.AU"],"gpt_icon":1},{"id":"2492453305","title":"Why the Mesoblast share price is diving 18% after an FDA win","url":"https://stock-news.laohu8.com/highlight/detail?id=2492453305","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492453305?lang=en_us&edition=fundamental","pubTime":"2024-12-20 08:54","pubTimestamp":1734656042,"startTime":"0","endTime":"0","summary":"The Mesoblast Ltd  share price is taking a nosedive today.  Shares in the S&P/ASX 300 Index  clinical-stage biotechnology company closed yesterday trading for $3.05. In late morning trade on Friday, shares are changing hands for $2.49 apiece, down 18.4%. For some context, the ASX 300 is down 0.9% at this same time.  So, why is the Mesoblast share price tumbling just one day after announcing a major US Food and Drug Administration  success?What's going on with the Mesoblast share price today?Well, it looks like investors aren't favouring their sell buttons today despite yesterday's big FDA news, but rather because of it. With no fresh news out from the ASX biotech stock today, we can only conclude that the selling action pressuring the Mesoblast share price is being driven by some healthy profit-taking. You see, investors reacted quite exuberantly to yesterday's news that the FDA had approved the company's Ryoncil  product as the first mesenchymal stromal cell  therapy in the United Sta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/20/why-the-mesoblast-share-price-is-diving-18-after-an-fda-win/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7508","MESO","MSB.AU","XKO.AU","MSC","BK4150","BK4139","BK4575","BK7501"],"gpt_icon":0},{"id":"2492486534","title":"MESO Stock Up as FDA Approves Ryoncil for Graft Versus Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492486534","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492486534?lang=en_us&edition=fundamental","pubTime":"2024-12-20 02:16","pubTimestamp":1734632160,"startTime":"0","endTime":"0","summary":"Mesoblast Limited MESO announced that the FDA has approved Ryoncil  for the treatment of steroid-refractory acute graft versus host disease  in children aged two months and older, including adolescents and teenagers.Following the FDA nod, Ryoncil became the first and only mesenchymal stromal cell therapy to be approved for any indication in the United States.Ryoncil is also the first FDA-approved therapy for pediatric SR-aGvHD, a life-threatening condition with high mortality rates.Shares of MESO were up 40.4% in after-hours trading on Dec. 18. The stock has skyrocketed 456.8% in the year so far against the industry’s decline of 10.5%.The FDA approval was based on data from the phase III study which evaluated Ryoncil for treating children with SR-aGvHD.Data from the same showed that out of 89% of children who had high severity grade C or grade D disease, 70% achieved an overall response by day 28 following treatment with Ryoncil, a measure that predicts survival in aGVHD.A better-ranke","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/meso-stock-fda-approves-ryoncil-181600672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFTCPJ56.SGD","IE0009355771.USD","BK4585","IE0002141913.USD","IE00B2B36J28.USD","INCY","MESO","BK4588","LU0211331839.USD","BK4139","BK4578","BK4007","BK4218","SPRO","BK4532","HST","BK4550","IE00B4R5TH58.HKD","MSB.AU","IE00BJJMRZ35.SGD","NVS","BK4181","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2492044351","title":"Mesoblast Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2492044351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492044351?lang=en_us&edition=fundamental","pubTime":"2024-12-20 01:53","pubTimestamp":1734630780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MESO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 12:53 ET (17:53 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","MSB.AU"],"gpt_icon":0},{"id":"2492179141","title":"U.S.-Listed Shares of Mesoblast up 44% After FDA Approves Cell Therapy for Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492179141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492179141?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:36","pubTimestamp":1734618963,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NK15V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","MESO","BK4139","MSB.AU","BK7501"],"gpt_icon":0},{"id":"2492285861","title":"BUZZ-Mesoblast gains on FDA nod for graft-versus-host disease cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492285861","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492285861?lang=en_us&edition=fundamental","pubTime":"2024-12-19 18:50","pubTimestamp":1734605443,"startTime":"0","endTime":"0","summary":"BUZZ-Mesoblast gains on FDA nod for graft-versus-host disease cell therapy  ** U.S.-listed shares of Australia-based Mesoblast MSB.AX rise 44.2% to $17.67 premarket  ** The U.S. Food and Drug Administration late on Wednesday approved co's cell therapy for treating graft-versus-host disease   ** The therapy, branded as Ryoncil, is approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard steroid therapy ** GVHD is a complication that might occur after a cell transplant, where the donated stem cells attack the recipient's cells, mistaking them for an unfamiliar threat** Up to last close, stock rose ~457% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK0VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","MSB.AU","BK7501"],"gpt_icon":0},{"id":"2492141398","title":"U.S.-Listed Shares of Mesoblast Surge 49% Premarket After FDA Approves Cell Therapy for Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492141398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492141398?lang=en_us&edition=fundamental","pubTime":"2024-12-19 17:21","pubTimestamp":1734600119,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nL4N3NK0SX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MESO","BK7501","MSB.AU","BK4139","BK7067"],"gpt_icon":0},{"id":"2492194244","title":"Why Champion Iron, EBR Systems, Mesoblast, and Patriot Battery Metals shares are surging today","url":"https://stock-news.laohu8.com/highlight/detail?id=2492194244","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492194244?lang=en_us&edition=fundamental","pubTime":"2024-12-19 10:55","pubTimestamp":1734576924,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is having a very disappointing session following a selloff on Wall Street overnight. In afternoon trade, the benchmark index is down 1.85% to 8,154.7 points. Four ASX s","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/19/why-champion-iron-ebr-systems-mesoblast-and-patriot-battery-metals-shares-are-surging-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","BK7129","BK4575","MSB.AU","MESO","PAI","BK7501","PAI.AU","BK7067","IE00B1B80R65.USD","CIA.AU","EBR","BK7095","BK7007","PMT.AU","BK4150","EBR.AU","BK7508","MSC","BK4081","XJO.AU"],"gpt_icon":0},{"id":"2492953921","title":"BUZZ-Australia's Mesoblast at 4-yr high on US FDA nod for cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492953921","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492953921?lang=en_us&edition=fundamental","pubTime":"2024-12-19 10:12","pubTimestamp":1734574366,"startTime":"0","endTime":"0","summary":"** Shares of Mesoblast    rise as much as 46% to A$2.890, their highest since Dec. 16, 2020   ** Stock posts its biggest intraday percentage rise since April 2   ** Drug developer says U.S. Food and Drug Administration approved co's cell therapy for graft-versus-host disease   ** About 28.1 mln shares change hands, compared with the 30-day average volume of around 6.3 mln   ** Stock up over 825% YTD, including session's move ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","XJO.AU","MSB.AU","XAO.AU","BK7508","XKO.AU","BK7501"],"gpt_icon":1},{"id":"2492193506","title":"Mesoblast’s Ryoncil becomes first cell therapy approved in the US for acute graft-versus-host disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492193506","media":"Small Caps","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492193506?lang=en_us&edition=fundamental","pubTime":"2024-12-19 08:59","pubTimestamp":1734569971,"startTime":"0","endTime":"0","summary":"Regenerative medicine company Mesoblast  has been granted US Food and Drug Administration  approval for its Ryoncil therapy to treat children with steroid-refractory acute graft-versus-host disease .The off-the-shelf drug derived from bone marrow has become the first mesenchymal stromal cell therapy on the US market to treat the condition, which can occur after a bone marrow or stem cell transplant and has both a poor prognosis and high mortality rate.Ryoncil will be available from today as an intravenous infusion at US transplant centres and other treating hospitals.Mesoblast chief executive Dr Silviu Itescu welcomed the FDA’s decision.“We are very pleased that the FDA has granted approval of Ryoncil and we are proud of our commitment to the GvHD community in bringing this important new treatment to children and families with no other acceptable options,” he said.“We will continue to work closely with the regulator to obtain approval of our other late-stage products, including Revasco","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/12/Mesoblast-ASX-MSB-Ryoncil-FDA-approval-mesenchymal-stromal-cell.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/12/Mesoblast-ASX-MSB-Ryoncil-FDA-approval-mesenchymal-stromal-cell.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/mesoblast-ryoncil-cell-therapy-fda-approved-acute-graft-versus-host-disease/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7508","BK7067","MESO","BK4139","MSB.AU","BK7501"],"gpt_icon":1},{"id":"2492948162","title":"Mesoblast Receives US FDA Approval for Mesenchymal Stromal Cell Therapy; Shares Hit Four-Year High","url":"https://stock-news.laohu8.com/highlight/detail?id=2492948162","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492948162?lang=en_us&edition=fundamental","pubTime":"2024-12-19 08:53","pubTimestamp":1734569612,"startTime":"0","endTime":"0","summary":"Mesoblast  received US Food and Drug Administration approval for mesenchymal stromal cell  therapy, Ryoncil, according to a Thursday filing with the Australian bourse.Ryoncil is the only MSC therapy approved in the US for any indication and the only approved therapy for steroid-refractory acute graft-versus-host disease  in children two months and older, the filing said.SR-aGvHD is a stem cell transplant complication where a patient's disease doesn't respond to high-dose steroids.Shares rose nearly 33% in morning trade Thursday and earlier reached their highest since December 2020.Price : $2.63, Change: $+0.65, Percent Change: +32.83%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MSC","BK4575","LU1043141123.HKD","LU2238339852.HKD","LU0426412945.USD","LU0994945656.USD","AUD","BK7067","BK7501","LU0345774631.USD","BK7508","BK4139","MSB.AU","BK4150","MESO","BK4125","LU0426417589.USD"],"gpt_icon":1},{"id":"2492161377","title":"Mesoblast’s Ryoncil® Is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2492161377","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492161377?lang=en_us&edition=fundamental","pubTime":"2024-12-19 08:09","pubTimestamp":1734566963,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nFWN3NJ10R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MESO","MSB.AU","BK7508","BK7501","BK4139","BK7067"],"gpt_icon":0},{"id":"2492697521","title":"Mesoblast share price rockets 30% on big US FDA news","url":"https://stock-news.laohu8.com/highlight/detail?id=2492697521","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492697521?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:46","pubTimestamp":1734565600,"startTime":"0","endTime":"0","summary":"The market is a sea of red on Thursday but that isn't stopping the Mesoblast Ltd  share price from rocketing. In morning trade, the allogeneic cellular medicines developer's shares are up 30% to a 52-week high of $2.57. Why is the Mesoblast share price shooting higher?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/19/mesoblast-share-price-rockets-30-on-big-us-fda-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","BK7508","BK7501","BK4150","BK4575","MESO","MSC","MSB.AU","BK7067"],"gpt_icon":1},{"id":"2492166865","title":"Mesoblast ADRs Rise 22%, Company Joining Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492166865","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492166865?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:20","pubTimestamp":1734564000,"startTime":"0","endTime":"0","summary":"The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the company will be added to the Nasdaq Biotechnology Index, effective Dec. 23.After the bell, the company's ADRs were trading 22% higher, at $14.98. They ended the day's regular session with a 2% loss, closing at $12.25.Mesoblast said it develops allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","MSB.AU","BK4139","BK7508","SQQQ","NDAQ",".IXIC","TQQQ","BK4588","MESO","QID","BK4585","USAW.SI","IE00B64PRP62.GBP","NVIW.SI","USJW.SI","QLD","MNQmain","IE00BKPKM429.USD","TSYW.SI","BK7501","LU2095319765.USD","PSQ","NQmain","BK7067","LU2210150020.SGD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2492116518","title":"BRIEF-FDA Approves First Mesenchymal Stromal Cell Therapy To Treat Steroid-Refractory Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492116518","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492116518?lang=en_us&edition=fundamental","pubTime":"2024-12-19 07:13","pubTimestamp":1734563639,"startTime":"0","endTime":"0","summary":"Dec 18  -    * FDA: APPROVES FIRST MESENCHYMAL STROMAL CELL THERAPY TO TREAT STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE   * FDA: GRANTED APPROVAL OF RYONCIL TO MESOBLAST, INC.   * FDA: APPROVED RYONCIL TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE IN PEDIATRIC PATIENTS 2 MONTHS OF AGE & OLDERSource text:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","HST","MESO","BK4218","MSB.AU","BK4181","BK7501","BK7508","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2492163080","title":"Mesoblast Ltd-FDA Approves Mesoblast Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2492163080","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492163080?lang=en_us&edition=fundamental","pubTime":"2024-12-19 06:59","pubTimestamp":1734562744,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUEK2SNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MSB.AU","BK7508","BK7501"],"gpt_icon":0},{"id":"2492997157","title":"US FDA approves Mesoblast's cell therapy for graft-versus-host disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2492997157","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492997157?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:50","pubTimestamp":1734558605,"startTime":"0","endTime":"0","summary":"US FDA approves Mesoblast's cell therapy for graft-versus-host diseaseDec 18  - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's MSB.AX cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL4N3NJ1H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","MSB.AU"],"gpt_icon":0},{"id":"2492615733","title":"FDA: Approved Ryoncil Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease in Pediatric Patients 2 Months of Age & Older","url":"https://stock-news.laohu8.com/highlight/detail?id=2492615733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492615733?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:41","pubTimestamp":1734558078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nFWN3NJ10F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7067","BK7501","MSB.AU","MESO","BK7508"],"gpt_icon":0},{"id":"2492578581","title":"FDA: Granted Approval of Ryoncil to Mesoblast, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2492578581","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492578581?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:41","pubTimestamp":1734558078,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nFWN3NJ10F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7508","BK4139","BK7067","BK7501","MESO"],"gpt_icon":0},{"id":"2492188611","title":"BRIEF-Mesoblast To Be Added To Nasdaq Biotechnology Index","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188611","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492188611?lang=en_us&edition=fundamental","pubTime":"2024-12-18 20:56","pubTimestamp":1734526599,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast To Be Added To Nasdaq Biotechnology IndexDec 18 (Reuters) - Mesoblast Ltd MSB.AX:MESOBLAST TO BE ADDED TO NASDAQ BIOTECHNOLOGY INDEXSource text: ID:nGNXc0QfgyFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA28CKHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","LU2095319765.USD","LU2210149790.SGD","MSB.AU","NDAQ","IE00B64PRP62.GBP","BK4112","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK7508","IE00BGHQF748.EUR","LU2210150020.SGD","BK7501","BK4585","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":7,"totalSize":166,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[]}}